Relationship between the expression of ERCC-1, survivin and both efficiency and prognosis of cisplatin contained first-line chemotherapy in advanced lung adenocarcinoma

  • Xiaobing Chen
  • Suxia Luo
  • Ning Li
  • Yongping Song
  • Junjie Zen
Article

DOI: 10.1007/s10330-009-0043-5

Cite this article as:
Chen, X., Luo, S., Li, N. et al. Chin. -Ger. J. Clin. Oncol. (2009) 8: 265. doi:10.1007/s10330-009-0043-5

Abstract

Objective

We analyzed the relationship between the expression of ERCC-1 (excisition repair cross complement-1), survivin and sensitivity and prognosis of cisplatin contained regimens first-line chemotherapy in advanced lung adenocarcinoma.

Methods

Immunohistochemical (IHC) method was used to evaluate the expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line chemotherapy. The response rate and survival time were analyzed according to the expression of ERCC-1 and survivin.

Results

Only 77 patients could be reviewed by IHC staining. The expression rates of ERCC-1 and survivin were 33.77% and 53.25 % respectively. The worse response rate and shorter TTP/ PFS could be identified in ERCC-1 positive group. Patients with positive expression of survivin had worse survival time.

Conclusion

Expression of ERCC-1 may be a molecular marker of cisplatincontained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma patients. Positive expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.

Key words

lung adenocarcinoma ERCC-1 survivin cisplatin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Xiaobing Chen
    • 1
    • 2
  • Suxia Luo
    • 1
    • 2
  • Ning Li
    • 2
  • Yongping Song
    • 2
  • Junjie Zen
    • 2
  1. 1.The First Affiliated Hospital of Zhengzhou UniversityHe’nan Province Tumor HospitalZhengzhouChina
  2. 2.Medicine DepartmentHe’nan Province Tumor HospitalZhengzhouChina

Personalised recommendations